Three novel functional polymorphisms in the promoter of FGFR2 gene and breast cancer risk: a HuGE review and meta-analysis

被引：0
作者：
Liping Zhou
Fan Yao
Hong Luan
Yinling Wang
Xihua Dong
Wenwen Zhou
Qihui Wang
机构：
[1] The First Affiliated Hospital of China Medical University,Department of Laboratory Medicine
[2] The First Affiliated Hospital of China Medical University,Department of Breast Surgery
来源：
Breast Cancer Research and Treatment | 2012年 / 136卷
关键词：
Breast cancer; Fibroblast growth factor receptor 2; Polymorphism; Meta-analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Published data on the association between three novel functional polymorphisms (rs11200014, rs2981579, and rs2981578) in the promoter of FGFR2 gene and breast cancer risk are inconclusive. The aim of this human genome epidemiology review and meta-analysis was to derive a more precise estimation of the relationship. A literature search of Pubmed, Embase, Web of science, and CBM databases from inception through July 2012 was conducted. Seventeen studies were included with a total of 21,742 breast cancer cases and 31,125 healthy controls. Crude odds ratios (ORs) with 95 % confidence intervals (CIs) were used to assess the strength of association in allele model, dominant model, recessive model, homozygous model, and heterozygous model. When all the eligible studies were pooled into the meta-analysis, remarkable associations between the rs11200014 (A>G) polymorphism and breast cancer risk were detected in Caucasians (G vs. A: OR = 1.28, 95 % CI: 1.21–1.35; GG/AG vs. AA: OR = 1.32, 95 % CI: 1.18–1.48), but not in Asians and Africans. In addition, there were statistically significant associations between the rs2981579 (G>A) polymorphism and increased risk of breast cancer risk in all ethnicities (A vs. G: OR = 1.20, 95 % CI: 1.11–1.29; AA/GA vs. GG: OR = 1.32, 95 % CI: 1.18–1.48; AA vs. GG: OR = 1.67, 95 % CI: 1.55–1.81), including Caucasians, Asians, and Africans. However, the TT genotype of rs2981578 (C>T) polymorphism might decrease breast cancer risk (TT vs. CC/CT: OR = 0.55, 95 % CI: 0.38–0.79; TT vs. CC: OR = 0.51, 95 % CI: 0.35–0.76; TT vs. CT: OR = 0.58, 95 % CI: 0.40–0.85), especially among Asians. Results from the current meta-analysis indicates that three novel functional polymorphisms (rs11200014, rs2981579, and rs2981578) in the promoter of FGFR2 gene are associated with breast cancer susceptibility and might be a potential biomarkers for breast cancer risk.
引用
收藏
页码：885 / 897
页数：12
相关论文
共 572 条
  • [11] Nelson HD(1996)FGFR2 exon IIIa and IIIc mutations in Crouzon, Jackson-Weiss, and Pfeiffer syndromes: evidence for missense changes, insertions, and a deletion due to alternative RNA splicing Am J Hum Genet 58 491-54
  • [12] Walker M(2008)Cancer genomics and genetics of FGFR2 (Review) Int J Oncol 33 233-186
  • [13] Zakher B(2009)Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma Mol Cancer Res 7 41-731
  • [14] Mitchell J(2005)Fibroblast growth factor signaling in tumorigenesis Cytokine Growth Factor Rev 16 179-874
  • [15] Saether S(2007)Differential signal transduction of alternatively spliced FGFR2 variants expressed in human mammary epithelial cells J Cell Physiol 210 720-1093
  • [16] Bakken K(2007)A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer Nat Genet 39 870-324
  • [17] Lund E(2007)Genome-wide association study identifies novel breast cancer susceptibility loci Nature 447 1087-528
  • [18] Yang XR(2011)Genetic polymorphisms and breast cancer risk: evidence from meta-analyses, pooled analyses, and genome-wide association studies Breast Cancer Res Treat 127 309-424
  • [19] Chang-Claude J(2010)Quantitative assessment of the effect of FGFR2 gene polymorphism on the risk of breast cancer Breast Cancer Res Treat 124 521-292
  • [20] Goode EL(2010)Current evidence on the relationship between three polymorphisms in the FGFR2 gene and breast cancer risk: a meta-analysis Breast Cancer Res Treat 124 419-1558
12345678910